SAN
DIEGO, June 8, 2023 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs
44th Annual Global Healthcare Conference on Thursday, June 15, 2023 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) in Dana Point, CA. Kevin
Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will
present at the conference.
The live presentation will be webcast and may be accessed on
Neurocrine Biosciences' website under Investors at
www.neurocrine.com. A replay of the webcast will be available on
the website approximately one hour after the conclusion of the
event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is
a neuroscience-focused, biopharmaceutical company with a simple
purpose: to relieve suffering for people with great needs, but few
options. We are dedicated to discovering and developing
life-changing treatments for patients with under-addressed
neurological, neuroendocrine, and neuropsychiatric disorders. The
company's diverse portfolio includes FDA-approved treatments for
tardive dyskinesia, Parkinson's disease, endometriosis* and uterine
fibroids*, as well as a robust pipeline including multiple
compounds in mid- to late-phase clinical development across our
core therapeutic areas. For three decades, we have applied our
unique insight into neuroscience and the interconnections between
brain and body systems to treat complex conditions. We relentlessly
pursue medicines to ease the burden of debilitating diseases and
disorders, because you deserve brave science. For more information,
visit neurocrine.com, and follow the company on LinkedIn,
Twitter and Facebook. (*in collaboration with AbbVie)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conference-301846543.html
SOURCE Neurocrine Biosciences, Inc.